Biofarm Bucure (BIO) - Total Liabilities
Based on the latest financial reports, Biofarm Bucure (BIO) has total liabilities worth RON85.86 Million RON (≈ $19.71 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Biofarm Bucure net asset momentum to track the company's year-over-year net asset growth rate.
Biofarm Bucure - Total Liabilities Trend (2019–2025)
This chart illustrates how Biofarm Bucure's total liabilities have evolved over time, based on quarterly financial data.
Biofarm Bucure Competitors by Total Liabilities
The table below lists competitors of Biofarm Bucure ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gaumont SA
PA:GAM
|
France | €188.78 Million |
|
Orion Engineered Carbons SA
F:0OE
|
Germany | €1.52 Billion |
|
American Integrity Insurance Group, Inc.
NYSE:AII
|
USA | $888.05 Million |
|
GomSpace Group AB
ST:GOMX
|
Sweden | Skr358.66 Million |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $47.37 Million |
|
Cantor Equity Partners II, Inc.
NASDAQ:CEPT
|
USA | $6.13 Million |
|
Tufton Oceanic Assets Ltd
LSE:SHIP
|
UK | $9.36 Million |
|
Huaiji Dengyun Auto-parts Holding Co Ltd
SHE:002715
|
China | CN¥369.03 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biofarm Bucure's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biofarm Bucure's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biofarm Bucure (2019–2025)
The table below shows the annual total liabilities of Biofarm Bucure from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | RON85.86 Million ≈ $19.71 Million |
+11.19% |
| 2024-09-30 | RON77.22 Million ≈ $17.73 Million |
+29.99% |
| 2023-09-30 | RON59.40 Million ≈ $13.64 Million |
-31.31% |
| 2022-09-30 | RON86.48 Million ≈ $19.86 Million |
+0.57% |
| 2021-09-30 | RON85.99 Million ≈ $19.75 Million |
+6.39% |
| 2020-09-30 | RON80.82 Million ≈ $18.56 Million |
-9.58% |
| 2019-09-30 | RON89.39 Million ≈ $20.52 Million |
-- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more